Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations.

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Guergueltcheva V
  • Müller JS
  • Dusl M
  • Senderek J
  • Oldfors A
  • Lindbergh C
  • Maxwell S
  • Colomer J
  • Mallebrera CJ
  • Nascimento A
  • Muelas N
  • Kirschner J
  • Nafissi S
  • Kariminejad A
  • Nilipour Y
  • Bozorgmehr B
  • Najmabadi H
  • Rodolico C
  • Sieb JP
  • Schlotter B
  • Schoser B
  • Herrmann R
  • Voit T
  • Steinlein OK
  • Najafi A
  • Urtizberea A
  • Soler DM
  • Muntoni F
  • Hanna MG
  • Chaouch A
  • Straub V
  • Bushby K
  • Palace J
  • Beeson D
  • Abicht A
  • Lochmüller H

Grups d'Investigació

Abstract

Congenital myasthenic syndrome (CMS) is a clinically and genetically heterogeneous group of inherited disorders of the neuromuscular junction. A difficult to diagnose subgroup of CMS is characterised by proximal muscle weakness and fatigue while ocular and facial involvement is only minimal. DOK7 mutations have been identified as causing the disorder in about half of the cases. More recently, using classical positional cloning, we have identified mutations in a previously unrecognised CMS gene, GFPT1, in a series of DOK7-negative cases. However, detailed description of clinical features of GFPT1 patients has not been reported yet. Here we describe the clinical picture of 24 limb-girdle CMS (LG-CMS) patients and pathological findings of 18 of them, all carrying GFPT1 mutations. Additional patients with CMS, but without tubular aggregates, and patients with non-fatigable weakness with tubular aggregates were also screened. In most patients with GFPT1 mutations, onset of the disease occurs in the first decade of life with characteristic limb-girdle weakness and fatigue. A common feature was beneficial and sustained response to acetylcholinesterase inhibitor treatment. Most of the patients who had a muscle biopsy showed tubular aggregates in myofibers. Analysis of endplate morphology in one of the patients revealed unspecific abnormalities. Our study delineates the phenotype of CMS associated with GFPT1 mutations and expands the understanding of neuromuscular junction disorders. As tubular aggregates in context of a neuromuscular transmission defect appear to be highly indicative, we suggest calling this condition congenital myasthenic syndrome with tubular aggregates (CMS-TA).

Dades de la publicació

ISSN/ISSNe:
0340-5354, 1432-1459

JOURNAL OF NEUROLOGY  SPRINGER HEIDELBERG

Tipus:
Article
Pàgines:
838-850
PubMed:
21975507
Factor d'Impacte:
1,468 SCImago
Quartil:
Q1 SCImago

Cites Rebudes en Web of Science: 61

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Congenital myasthenic syndromes, Dok-7, GFPT1, Limb-girdle myasthenia, Tubular aggregates

Projectes associats

INVESTIGACION EN RED DE LAS ENFERMEDADES NEUROLOGICAS

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

C03/06 . INSTITUTO DE SALUD CARLOS III . 2003

PROYECTO CAIBER

CAI08/01/0061 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009

TRANSLATIONAL RESEARCH, EXPERIMENTAL MEDICINE AND THERAPEUTICS ON CHARCOT-MARIE-TOOTH. TREAT-CMT

Investigador Principal: JOSÉ MARÍA MILLÁN SALVADOR

TREAT-CMT . CIBER ENFERMEDADES RARAS; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

REGISTRO DEL SÍNDROME MIASTÉNICO DE LAMBERT-EATON.

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

BIO-AMI-2010-01 . 2014

ESTUDIO DE EXTENSIÓN ABIERTO DE LA SEGURIDAD, TOLERABILIDAD Y EFICACIA A LARGO PLAZO DE GSK2402968 EN SUJETOS CON DISTROFIA MUSCULAR DE DUCHENNE.

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

DMD114349 . 2012

ESTUDIO ABIERTO PARA PACIENTES CON DISTROFINOPATÍA POR MUTACIÓN SIN SENTIDO TRATADOS PREVIAMENTE CON ATALURENO (PTC124®).

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

PTC124-GD-019-DMD . 2012

ENSAYO CLÍNICO DE FASE III, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE GSK2402968 EN SUJETOS CON DISTROFIA MUSCULAR DE DUCHENNE.

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

DMD114044

ESTUDIO DE FASE III, A DOBLE CIEGO, ALEATORIZADO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA, SEGURIDAD Y TOLERABILIDAD DE LA IDEBENONA EN PACIENTES DE 10 A 18 AÑOS CON DISTROFIA MUSCULAR DE DUCHENNE.

Investigador Principal: JUAN JESÚS VÍLCHEZ PADILLA

SNT-III-003

Compartir la publicació